"Nigel Wild, head of consultancy Nigel Wild Associates, discovers how computers are being used to predict the effectiveness of cancer drugs". Features an interview of Dr Christophe Chassagnole, Physiomics Chief Operating Officer.
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year of a specific project studying cancer cellular processes for drugs targeting the cell cycle (the natural process of controlling cell proliferation)
Physiomics plc, the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the 2008 AACR Annual Meeting, taking place in San Diego, on 12-16 April 2008. Dr Eric Fernandez will present a development update on the Company’s chronotherapy research program, as part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics) project. The abstract will be published in the 2008 Proceeding of the AACR and will be presented in the poster session “Cellular and Molecular Biology 8”, scheduled for 1:00 pm on 13 April.
